The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.
Patients who require dialysis are at high risk for cardiovascular mortality, which may be improved by mineralocorticoid receptor antagonists (MRAs).Systematic review and meta-analysis of randomized controlled trials.Adults undergoing long-term hemodialysis or peritoneal dialysis with or without hear...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2016
|
| _version_ | 1797082501469962240 |
|---|---|
| author | Quach, K Lvtvyn, L Baigent, C Bueti, J Garg, A Hawley, C Haynes, R Manns, B Perkovic, V Rabbat, C Wald, R Walsh, M |
| author_facet | Quach, K Lvtvyn, L Baigent, C Bueti, J Garg, A Hawley, C Haynes, R Manns, B Perkovic, V Rabbat, C Wald, R Walsh, M |
| author_sort | Quach, K |
| collection | OXFORD |
| description | Patients who require dialysis are at high risk for cardiovascular mortality, which may be improved by mineralocorticoid receptor antagonists (MRAs).Systematic review and meta-analysis of randomized controlled trials.Adults undergoing long-term hemodialysis or peritoneal dialysis with or without heart failure.Randomized controlled trials evaluating an MRA in dialysis and reported at least one outcome of interest.Spironolactone (8 trials) or eplerenone (1 trial) compared to placebo (7 trials) or standard of care (2 trials).Cardiovascular and all-cause mortality, hyperkalemia, serum potassium level, hypotension, change in blood pressure, and gynecomastia.We identified 9 trials including 829 patients. The overall quality of evidence was low due to methodologic limitations in most of the included trials. The relative risk (RR) for cardiovascular mortality was 0.34 (95% CI, 0.15-0.75) for MRA-treated compared with control patients. The RR for all-cause mortality was 0.40 (95% CI, 0.23-0.69). The RR for hyperkalemia for MRA treatment was 3.05 (95% CI, 1.21-7.70). Sensitivity analyses demonstrated wide variability in RRs for cardiovascular mortality, all-cause mortality, and hyperkalemia, suggesting further uncertainty in the confidence of the primary results.Trial quality and size insufficient to robustly and precisely identify a treatment effect.Given the uncertainty of both the benefits and harms of MRAs in dialysis, large high-quality trials are required. |
| first_indexed | 2024-03-07T01:28:51Z |
| format | Journal article |
| id | oxford-uuid:92e70303-517e-415f-8c82-95e2d6296dee |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:28:51Z |
| publishDate | 2016 |
| record_format | dspace |
| spelling | oxford-uuid:92e70303-517e-415f-8c82-95e2d6296dee2022-03-26T23:28:44ZThe Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:92e70303-517e-415f-8c82-95e2d6296deeEnglishSymplectic Elements at Oxford2016Quach, KLvtvyn, LBaigent, CBueti, JGarg, AHawley, CHaynes, RManns, BPerkovic, VRabbat, CWald, RWalsh, MPatients who require dialysis are at high risk for cardiovascular mortality, which may be improved by mineralocorticoid receptor antagonists (MRAs).Systematic review and meta-analysis of randomized controlled trials.Adults undergoing long-term hemodialysis or peritoneal dialysis with or without heart failure.Randomized controlled trials evaluating an MRA in dialysis and reported at least one outcome of interest.Spironolactone (8 trials) or eplerenone (1 trial) compared to placebo (7 trials) or standard of care (2 trials).Cardiovascular and all-cause mortality, hyperkalemia, serum potassium level, hypotension, change in blood pressure, and gynecomastia.We identified 9 trials including 829 patients. The overall quality of evidence was low due to methodologic limitations in most of the included trials. The relative risk (RR) for cardiovascular mortality was 0.34 (95% CI, 0.15-0.75) for MRA-treated compared with control patients. The RR for all-cause mortality was 0.40 (95% CI, 0.23-0.69). The RR for hyperkalemia for MRA treatment was 3.05 (95% CI, 1.21-7.70). Sensitivity analyses demonstrated wide variability in RRs for cardiovascular mortality, all-cause mortality, and hyperkalemia, suggesting further uncertainty in the confidence of the primary results.Trial quality and size insufficient to robustly and precisely identify a treatment effect.Given the uncertainty of both the benefits and harms of MRAs in dialysis, large high-quality trials are required. |
| spellingShingle | Quach, K Lvtvyn, L Baigent, C Bueti, J Garg, A Hawley, C Haynes, R Manns, B Perkovic, V Rabbat, C Wald, R Walsh, M The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. |
| title | The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. |
| title_full | The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. |
| title_fullStr | The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. |
| title_full_unstemmed | The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. |
| title_short | The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. |
| title_sort | safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis a systematic review and meta analysis |
| work_keys_str_mv | AT quachk thesafetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT lvtvynl thesafetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT baigentc thesafetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT buetij thesafetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT garga thesafetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT hawleyc thesafetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT haynesr thesafetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT mannsb thesafetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT perkovicv thesafetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT rabbatc thesafetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT waldr thesafetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT walshm thesafetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT quachk safetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT lvtvynl safetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT baigentc safetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT buetij safetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT garga safetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT hawleyc safetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT haynesr safetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT mannsb safetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT perkovicv safetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT rabbatc safetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT waldr safetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis AT walshm safetyandefficacyofmineralocorticoidreceptorantagonistsinpatientswhorequiredialysisasystematicreviewandmetaanalysis |